Focused On-demand Library for Lysosome membrane protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q14108

UPID:

SCRB2_HUMAN

Alternative names:

85 kDa lysosomal membrane sialoglycoprotein; CD36 antigen-like 2; Lysosome membrane protein II; Scavenger receptor class B member 2

Alternative UPACC:

Q14108; B4DKD8; E7EM68; Q53Y63

Background:

Lysosome membrane protein 2, also known as 85 kDa lysosomal membrane sialoglycoprotein, CD36 antigen-like 2, Lysosome membrane protein II, and Scavenger receptor class B member 2, plays a crucial role in cellular processes. It acts as a lysosomal receptor for glucosylceramidase targeting and serves as a receptor for enterovirus 71. This protein's involvement in these pathways underscores its importance in maintaining cellular homeostasis and defense mechanisms.

Therapeutic significance:

Lysosome membrane protein 2 is implicated in Epilepsy, progressive myoclonic 4, with or without renal failure, a disorder characterized by action and reflex myoclonus, epileptic seizures, and progressive neurodegeneration. Understanding the role of this protein could open doors to potential therapeutic strategies, especially considering its association with renal failure in some cases.